Activity of temocillin in a lethal murine model of infection of intra-abdominal origin due to KPC-producing Escherichia coli

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 7, 2016, Pages 1899-1904

  Alexandre, K ^a   Chau, F ^a,b   Gue rin F ^c,d   Massias, L ^a,e   Lefort, A ^a,b,e   Cattoir, V ^c,d   Fantin, B ^a,b,e  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ DE CAEN   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE KLEBSIELLA PNEUMONIAE CARBAPENEMASE 2; BETA LACTAMASE KLEBSIELLA PNEUMONIAE CARBAPENEMASE 3; BETA LACTAMASE OXA 48; CARBAPENEMASE; IMIPENEM; TEMOCILLIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; PENICILLIN DERIVATIVE;

ABDOMINAL INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; BLOOD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG STERILITY; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; IN VIVO STUDY; LIMIT OF QUANTITATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PERITONEAL FLUID; SPLEEN; SURVIVAL RATE; TREATMENT DURATION; WILD TYPE; ANIMAL; ASCITES FLUID; BACTEREMIA; CHEMISTRY; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; INTRAABDOMINAL INFECTIONS; MICROBIAL SENSITIVITY TEST; PATHOLOGY; PLASMA; SECRETION (PROCESS); SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; ASCITIC FLUID; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAMASES; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; INJECTIONS, SUBCUTANEOUS; INTRAABDOMINAL INFECTIONS; MICE; MICROBIAL SENSITIVITY TESTS; PENICILLINS; PLASMA; SPLEEN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84979010103     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw066     Document Type: Article

References (29)

1. Doi Y, Park YS, Rivera JI et al. Community-associated extendedspectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis 2013; 56: 641-8
2. Van Boeckel TP, Gandra S, Ashok A et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014; 14: 742-50
3. Pitout JDD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-66
4. Parienti JJ, Lucet JC, Lefort A et al. Empirical therapies among adults hospitalized for community-acquired upper urinary tract infections: a decision-tree analysis of mortality, costs, and resistance. Am J Infect Control 2015; 43: 53-9
5. Nordmann P, Naas T, Poirel L. Global spread of carbapenemaseproducing Enterobacteriaceae. Emerg Infect Dis 2011; 17: 1791-8
6. Davies TA, Marie Queenan A, Morrow BJ et al. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. J Antimicrob Chemother 2011; 66: 2298-307
7. Chen L, Hu H, Chavda KD et al. Complete sequence of a KPC-producing IncN multidrug-resistant plasmid from an epidemic Escherichia coli sequence type 131 strain in China. Antimicrob Agents Chemother 2014; 58: 2422-5
8. Poirel L, Bonnin RA, Nordmann P. Analysis of the resistome of a multidrug-resistant NDM-1-producing Escherichia coli strain by high-throughput genome sequencing. Antimicrob Agents Chemother 2011; 55: 4224-9
9. Munoz-Price LS, Poirel L, Bonomo RA et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13: 785-96
10. Naas T, Cuzon G, Gaillot O et al. When carbapenem-hydrolyzing β-lactamase KPC meets Escherichia coli ST131 in France. Antimicrob Agents Chemother 2011; 55: 4933-4
11. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med 2002; 113 Suppl 1A: 14S-9S
12. Wilcox CM, Dismukes WE. Spontaneous bacterial peritonitis. a review of pathogenesis, diagnosis, and treatment. Medicine (Baltimore) 1987; 66: 447-56
13. Lorber B, Swenson RM. The bacteriology of intra-abdominal infections. Surg Clin North Am 1975; 55: 1349-54
14. Adlerberth I, Strachan DP, Matricardi PM et al. Gut microbiota and development of atopic eczema in 3 European birth cohorts. J Allergy Clin Immunol 2007; 120: 343-50
15. Livermore DM, Warner M, Mushtaq S et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011; 37: 415-9
16. Soubirou JF, Rossi B, Couffignal C et al. Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15. J Antimicrob Chemother 2015; 70: 1466-72
17. Balakrishnan I, Awad-El-Kariem FM, Aali A et al. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2011; 66: 2628-31
18. Woodford N, Pike R, Meunier D et al. In vitro activity of temocillin against multidrug-resistant clinical isolates of Escherichia coli, Klebsiella spp. and Enterobacter spp., and evaluation of high-level temocillin resistance as a diagnostic marker for OXA-48 carbapenemase. J Antimicrob Chemother 2014; 69: 564-7
19. Adams-Haduch JM, Potoski BA, Sidjabat HE et al. Activity of temocillin against KPC-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 2009; 53: 2700-1
20. Lepeule R, Ruppe E, Le P et al. Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase. Antimicrob Agents Chemother 2012; 56: 1376-81
21. Bleibtreu A, Gros P-A, Laouènan C et al. Fitness, stress resistance, and extraintestinal virulence in Escherichia coli. Infect Immun 2013; 81: 2733-42
22. Docobo-Perez F, Lopez-Cerero L, Lopez-Rojas R et al. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model. Antimicrob Agents Chemother 2013; 57: 2109-13
23. De Jongh R, Hens R, Basma Vet al. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2007; 61: 382-8
24. Laterre P-F, Wittebole X, Van de Velde S et al. Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. J Antimicrob Chemother 2015; 70: 891-8
25. Signs SA, Tan JS, Salstrom SJ et al. Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration. Antimicrob Agents Chemother 1992; 36: 1400-3
26. Wise R, Donovan IA, Drumm J et al. The intraperitoneal penetration of temocillin. J Antimicrob Chemother 1983; 12: 93-6
27. Wittke RR, Adam D, Klein HE. Therapeutic results and tissue concentrations of temocillin in surgical patients. Drugs 1985; 29 Suppl 5: 221-6
28. Andrews JM, Jevons G, Walker R et al. Temocillin susceptibility by BSAC methodology. J Antimicrob Chemother 2007; 60: 185-7
29. Leggett JE, Ebert S, Fantin B et al. Comparative dose-effect relations at several dosing intervals for β-lactam, aminoglycoside and quinolone antibiotics against Gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis Suppl 1990; 74: 179-84